Loading
Gerresheimer AG Stock: price and insider trades · Germany
1 insider bought €12.4M of shares over the last 90 days, the latest filed 15 Sept 2026.
Gerresheimer AG: what insiders have been doing
Gerresheimer AG, classified in the Healthcare & Pharma sector, is a listed company based in Düsseldorf, Germany, founded in 1864. Its insiders report their share dealings to BaFin. In the past year (18 October 2025 to 18 October 2026), 17 filings came from 3 insiders.
Every open-market trade in the period is a purchase: 17 purchases worth €45.1M, from 3 insiders, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €9.6M, the purchase published on 8 May 2026 by AOC Gecko S.à r.l. is the largest of the period (1.1% of market cap).
In all, 10 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (15 September 2026) now reads 32 days. Between a trade and the moment it shows up on BaFin, the median delay is 6 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Across the 287 companies tracked on its exchange, the median is 5 filings; at 17 filings, this issuer sits above that mark. Our records for Gerresheimer AG go back to 2025, with 18 purchases and no sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from BaFin disclosures alone and does not predict where the share price will go.
Insider Decl.
18
Thresholds
n/a
Buy Volume
€45M
18 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleActive Ownership Opportunities SCS7 buys
Active Ownership Fund SICAV SIF SCS5 buys
AOC Gecko S.à r.l.5 buys
Dietmar Siemssen2 buys
Since the insiders bought
- +2.6%Entry €28.98 · Close 16 Oct 2026 €29.74
- +8.9%Entry €27.32 · Close 16 Oct 2026 €29.74
- +8.9%Entry €27.32 · Close 16 Oct 2026 €29.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Gerresheimer AG Hold (neutral), based on 12 analysts. Average price target: €27.38.
Fundamental score
Ranked 22,314 of 24,148 companies
19.4
score / 100
Value25
Quality13
FCF yld-10.0%
Earn yld-32%
EV/EBITDA10.9x
ROE-32%
Gross mgn18%
Net mgn-14%
Debt/EBITDA7.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended November 2025 · cache
€28.70
Analyst consensus
12 analystsHold
€20.00Target €27.38(-5%)€46.00
Income statement
Revenue€2.3B
Gross profit€425.3M18% margin
EBITDA€289.9M12% margin
Net income-€320.3M-17.5% margin
Valuation
PER (trailing)42.8x
PER (forward)9.4x
P/Book1.0x
Beta0.45
Balance sheet & cash
Market cap€991.3M
Total debt€2.2B
Free Cash Flow-€98.8M
Debt / Equity237%
Profitability & ownership
ROE-32.4%
ROA0.5%
% insiders11.4%
% institutions73.3%
Last declaration on 15 September 2026
Declarations18 total
73,391.105 shares@ €28.920.24% mcap17.1% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-303de7134863
Canonical exit: 10 Dec 2026 (T+90)
4,514.457 shares@ €28.620.014% mcap1.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-24334c45f51e
Canonical exit: 8 Dec 2026 (T+90)
27,558.518 shares@ €28.590.088% mcap6.4% of flowShareXetraISIN DE000A0LD6E6BAFIN:40006640-2d2d75394db9
Canonical exit: 7 Dec 2026 (T+90)
9,048.937 shares@ €27.990.028% mcap2.0% of flowShareXetraISIN DE000A0LD6E6BAFIN:40006640-968f4a894894
Canonical exit: 6 Dec 2026 (T+90)
3,982.47 shares@ €27.800.012% mcap0.9% of flowShareXetraISIN DE000A0LD6E6BAFIN:40006640-e7b6a1641c57
Canonical exit: 3 Dec 2026 (T+90)
75,248.935 shares@ €27.890.23% mcap16.9% of flowShareXetraISIN DE000A0LD6E6BAFIN:40006640-d2f3ab316ac8
Canonical exit: 2 Dec 2026 (T+90)
251,286.411 shares@ €27.420.77% mcap55.6% of flowShareXetraISIN DE000A0LD6E6BAFIN:40006640-65811a4892c1
Canonical exit: 30 Nov 2026 (T+90)
90,509.803 shares@ €28.250.30% mcap31.3% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-b7babe0194d2
Canonical exit: 10 Aug 2026 (T+90)
271,529.408 shares@ €28.250.90% mcap31.3% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-83eeb38843af
Canonical exit: 10 Aug 2026 (T+90)
15,749.129 shares@ €25.850.048% mcap5.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-e9c6e004deb7
Canonical exit: 4 Aug 2026 (T+90)
47,247.386 shares@ €25.850.14% mcap5.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-c1028fb6d221
Canonical exit: 4 Aug 2026 (T+90)
37,504.013 shares@ €25.700.11% mcap11.8% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-ab4211afc0e4
Canonical exit: 3 Aug 2026 (T+90)
112,512.038 shares@ €25.700.34% mcap11.8% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-3067e82b6c98
Canonical exit: 3 Aug 2026 (T+90)
127,520.051 shares@ €24.990.37% mcap13.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-1f3876c854f7
Canonical exit: 2 Aug 2026 (T+90)
42,506.684 shares@ €24.990.12% mcap13.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640-f696e7957caa
Canonical exit: 2 Aug 2026 (T+90)
132,505.495 shares@ €24.040.37% mcap39.0% of flowShareISIN DE000A0LD6E6BAFIN:40006640-3216f0103174
Canonical exit: 29 Jul 2026 (T+90)
397,516.485 shares@ €24.041.12% mcap39.0% of flowShareISIN DE000A0LD6E6BAFIN:40006640-4ea9b0a6a980
Canonical exit: 29 Jul 2026 (T+90)
2,000 shares@ €29.20100.0% of flowShareXETRAISIN DE000A0LD6E6BAFIN:40006640
Canonical exit: 8 Jan 2026 (T+90)
18 of 18 declarations
About Gerresheimer AG
Gerresheimer AG is a German industrial group focused on pharmaceutical packaging and drug-delivery systems. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX), the company is based in Germany, in Düsseldorf. Its roots go back to 1864, when Ferdinand Heye founded a glassworks in Gerresheim near Düsseldorf. Over time, the business evolved from a traditional glassmaker into a global supplier of higher-value solutions for the pharmaceutical, biotech, healthcare and cosmetics industries.
Today, Gerresheimer’s operating model is built around three main divisions: Plastics & Devices, Primary Packaging Glass and Advanced Technologies. The group develops and manufactures primary packaging and drug-delivery solutions designed to protect, store and simplify the administration of medicines. Its portfolio includes vials, ampoules, bottles, containers for solid and liquid medicines, closure systems, prefillable syringes, insulin pens, inhalers and connected devices. Gerresheimer also positions itself as a system and solution provider for more complex medicines, biologics and selected cosmetic applications, rather than merely a commodity packaging manufacturer.
Read moreShow less
From a competitive perspective, Gerresheimer holds a strong position in pharmaceutical primary packaging, a market supported by long-term structural drivers such as aging populations, the growth of biopharmaceuticals and rising regulatory requirements around safety, quality and traceability. The company’s global industrial footprint is a key asset: it operates more than 40 production plants worldwide and follows a “local for local” manufacturing approach across Europe, the Americas and Asia. This helps the group serve multinational pharma customers close to end markets while reducing supply-chain risk.
Recent developments have been significant. In fiscal 2024, Gerresheimer completed the acquisition of Bormioli Pharma in December 2024, broadening its product range and strengthening its closure-systems offering for pharma and biopharma customers. In 2025, the company announced an expansion of its Wertheim site in Germany, including a new facility for ready-to-fill vials aimed at sensitive biologics. More recently, on 10 February 2026, Gerresheimer said it was postponing publication of its 2025 annual and consolidated financial statements while internal investigations continued regarding revenue recognition and accounting practices for 2024 and 2025, and it also initiated the sale of Centor Inc. to optimize its capital and financing structure. For investors, Gerresheimer remains a structurally attractive healthcare packaging and devices story, but the latest governance and reporting developments warrant close monitoring.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
